 |
|
|
| |
DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS WITH HIV-1 INFECTION-
3-YEAR RESULTS FROM THE GEMINI STUDIES
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Pedro Cahn,1 Juan Sierra Madero,2 Jose Ramon Arribas,3 Andrea Antinori,4 Roberto Ortiz,5 Amanda E. Clarke,6 Chien-Ching Hung,7
Jürgen K. Rockstroh,8 Pierre-Marie Girard,9 Jorg Sievers,10 Choy Y. Man,11 Rimgaile Urbaityte,12 Mark Underwood,11 Keith A. Pappa,11
Kimberly Y. Smith,11 Martin Gartland,11 Michael Aboud,10 Jean van Wyk,10 Brian Wynne11
1Fundacion Huesped, Buenos Aires, Argentina; 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico; 3Hospital La Paz, Madrid, Spain; 4Istituto Nazionale per le Malattie Infettive
Lazzaro Spallanzani, Rome, Italy; 5Bliss Healthcare Services, Orlando, FL, USA; 6Royal Sussex County Hospital and Brighton & Sussex Medical School, Brighton, UK; 7National Taiwan University Hospital, Taipei, Taiwan; 8Rheinische Friedrich-Wilhelms Universitat, Bonn, Germany; 9Hopital Saint Antoine, Paris, France; 10ViiV Healthcare, Brentford, UK; 11ViiV Healthcare, Research Triangle Park, NC, USA; 12GlaxoSmithKline, Stockley Park, UK Presenting author: Pedro Cahn; pedro.cahn@huesped.org.ar
aWeek 144 analysis used a mixed-effect repeated-measures model. Mean change from baseline adjusted for study, treatment, visit, baseline HIV-1 RNA, baseline CD4+ cell count, age, sex, race, baseline biomarker value, treatment-by-visit interaction, and baseline biomarker value-by-visit interaction. For renal biomarkers, mean change from baseline was also adjusted for presence of diabetes and presence of hypertension. For bone biomarkers, mean change was also adjusted for BMI, smoking status, and current vitamin D use. bEstimated from geometric mean ratios for baseline and Week 144. Based on the same model as plasma/serum markers except adjusting for loge-transformed baseline biomarker. *P<0.01. **P<0.001.
|
| |
|
|
|
|
|
